Side-by-side · Research reference

HGH 191AAvsN-Acetyl Epitalon Amidate

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AFDA-ApprovedHUMAN-REVIEWED0/75 cited

BAnimal-StrongHUMAN-REVIEWED12/45 cited

HGH 191AA

Recombinant hGH · FDA-Approved

0.024–0.034 mg/kg/dayPediatric GHD dose

2–4 hoursPlasma half-life

191 AASequence length

SQ · Daily · Evening preferred

N-Acetyl Epitalon Amidate

Bioregulator Tetrapeptide · Khavinson School

10 passagesExtra divisionsKhavinson 2004

Telomerase+Enzyme inductionKhavinson 2003

4-AATetrapeptide

SQ · Variable protocols

01Mechanism of Action

Parameter

HGH 191AA

N-Acetyl Epitalon Amidate

Primary target

Growth hormone receptor (GHR) — JAK2/STAT5 pathway

DNA promoter regions (telomerase, RNA polymerase II, retinal genes)

Pathway

GHR activation → JAK2/STAT5 → liver IGF-1 synthesis + direct metabolic effects

Peptide → DNA complementary binding → Gene transcription initiation → Telomerase catalytic subunit expression

Downstream effect

Linear growth, lipolysis, protein synthesis, nitrogen retention, carbohydrate metabolism modulation

Telomerase enzymatic activity induction, telomere elongation to early-passage length, extension of replicative lifespan in human somatic cellsKhavinson 2003 Khavinson 2004

Feedback intact?

No — exogenous GH bypasses hypothalamic-pituitary axis, suppresses endogenous pulsatility

—

Origin

Recombinant DNA technology — 191 AA, identical to pituitary hGH, no methionyl residue

Synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from pineal extract bioregulator research; N-acetyl and C-amide modifications enhance plasma stability

Antibody development

Rare — <2% develop binding antibodies, typically non-neutralizing

—

02Dosage Protocols

Parameter

HGH 191AA

N-Acetyl Epitalon Amidate

Pediatric GHD

0.024–0.034 mg/kg/day SQ

6–7× per week dosing typical. Brand-specific ranges.

—

Adult GHD

0.004–0.016 mg/kg/day SQ

Start low, titrate based on IGF-1 levels.

—

Turner syndrome

0.045–0.050 mg/kg/day SQ

—

Idiopathic short stature

0.037 mg/kg/day SQ

—

AIDS wasting

0.1 mg/kg/day SQ (high-dose)

Short-term indication. Monitor glucose.

—

Frequency

Once daily, typically evening

Evening administration mimics physiological GH pulse.

Not specified in candidate papers

Evidence basis

FDA-approved / decades of RCT data

In vitro human cell cultureKhavinson 2004 Khavinson 2003

Monitoring

IGF-1, glucose, thyroid function, bone age (children)

—

Duration

Years (children until epiphyseal closure); indefinite (adult GHD)

Chronic treatment in aging culture

Sustained effect through late passages.

Standard dose

—

No standardized human dosing in indexed literature

In vitro protocols use direct culture addition; human clinical dosing protocols are in Russian-language literature outside PubMed scope.

Cell culture protocol

—

Addition to human fetal fibroblast culture induced telomerase activity and telomere elongation to early-passage lengthKhavinson 2004

Cells made 10 extra divisions (44 passages total vs 34 in control).

Modification stability

—

N-acetyl + C-amide caps enhance peptidase resistance

Standard strategy for tetrapeptide stabilization; specifics not quantified in candidates.

03Metabolic / Fat Loss Evidence

Parameter

HGH 191AA

N-Acetyl Epitalon Amidate

Primary fat target

Visceral and subcutaneous adipose tissue

—

Mechanism

Lipolysis via hormone-sensitive lipase activation, FFA oxidation

—

Effect on lean mass

Significant lean mass increase (protein synthesis, nitrogen retention)

—

Insulin sensitivity

Acute insulin resistance (anti-insulin effect); chronic neutral-to-improved via fat loss

—

IGF-1 elevation

Dose-dependent, significant — primary anabolic mediator

—

Glucose metabolism

Hyperglycemia risk, especially high doses (AIDS wasting)

—

Body composition

↓ fat mass, ↑ lean mass, ↑ bone mineral density (children)

—

Clinical context

FDA-approved for AIDS wasting (cachexia). Off-label use for body recomposition lacks long-term safety data.

—

04Side Effects & Safety

Parameter

HGH 191AA

N-Acetyl Epitalon Amidate

Injection site reaction

Lipohypertrophy, lipoatrophy, erythema (rotate sites)

—

Fluid retention / Edema

Peripheral edema, arthralgia, carpal tunnel syndrome (dose-dependent)

—

Glucose intolerance

Hyperglycemia, new-onset diabetes (anti-insulin effect)

—

Intracranial hypertension

Benign intracranial hypertension (pseudotumor cerebri) — headache, visual changes, papilledema

—

Slipped capital femoral epiphysis

SCFE risk in children — limp, hip/knee pain (requires surgery)

—

Scoliosis progression

Rapid growth may unmask/progress scoliosis (monitor spine in children)

—

Hypothyroidism

Central hypothyroidism unmasking or worsening (monitor TSH, free T4)

—

Cancer risk

Contraindicated in active malignancy. Theoretical risk in cancer survivors (controversial).

—

Antibody formation

Rare (<2%), typically non-neutralizing. Loss of efficacy if neutralizing antibodies develop.

—

Pancreatitis

Rare. Higher risk in children with certain syndromes (Prader-Willi).

—

Gynecomastia

Adolescent males (physiological during puberty, may be exacerbated)

—

Human safety data

—

Not available in indexed literature

Candidate papers describe in vitro and animal models only.

Theoretical telomerase risk

—

Telomerase activation in somatic cells raises theoretical oncogenic transformation concern

In vitro observations

—

No cytotoxicity reported in human fetal fibroblast cultureKhavinson 2004

Absolute Contraindications

HGH 191AA

·Active malignancy or history of cancer (especially childhood cancer survivors with risk factors)
·Acute critical illness (post-cardiac surgery, trauma, acute respiratory failure)
·Diabetic retinopathy (active proliferative or severe non-proliferative)
·Prader-Willi syndrome with severe obesity, sleep apnea, or respiratory impairment
·Closed epiphyses (for growth indications)

N-Acetyl Epitalon Amidate

·Active malignancy or history of cancer — telomerase reactivation may promote tumor cell immortalization

Relative Contraindications

HGH 191AA

·Diabetes mellitus (monitor closely, may require insulin adjustment)
·Intracranial lesions or history of intracranial hypertension
·Scoliosis (monitor curve progression)
·Untreated hypothyroidism (treat before GH initiation)
·Severe obesity (assess OSA risk, cardiovascular status)

N-Acetyl Epitalon Amidate

·Individuals with hereditary cancer syndromes or high genetic cancer risk

05Administration Protocol

Parameter

HGH 191AA

N-Acetyl Epitalon Amidate

1. Reconstitution (if lyophilized)

Add diluent (sterile water or bacteriostatic water per manufacturer) to vial. Swirl gently — do not shake. Solution should be clear, colorless. Concentration varies by brand (e.g., 5 mg or 10 mg per vial).

Subcutaneous injection assumed based on peptide class; no specific protocol in candidate papers.

2. Injection site

Subcutaneous — rotate sites: abdomen, thigh, buttocks, upper arm. Avoid same site within 1 cm for 2 weeks to prevent lipodystrophy.

Standard bacteriostatic water for lyophilized peptides. Exact volume not specified in indexed literature.

3. Timing

Once daily, evening preferred (6–8 PM or pre-sleep). Mimics physiological nocturnal GH secretion. Consistency is critical.

Lyophilized: -20 °C, desiccated. Reconstituted: refrigerate 2–8 °C. N-acetyl and C-amide modifications improve stability vs unprotected tetrapeptide.

4. Storage

Unreconstituted: refrigerate 2–8 °C, protect from light. Reconstituted: refrigerate, use within 14–28 days (brand-specific). Do not freeze.

Human dosing schedules published in Russian-language clinical literature; not indexed in PubMed candidate set.

5. Needle

27–31G, 4–8 mm insulin syringe or pen device. Pinch skin, 45–90° angle depending on subcutaneous thickness.

—

6. Monitoring

Baseline and periodic: IGF-1 (target age/sex-adjusted midrange), fasting glucose, HbA1c, thyroid function (TSH, free T4), bone age (children), lipid panel. Fundoscopy if headache/visual symptoms.

—

06Stack Synergy

HGH 191AA

+ Ipamorelin

Moderate

View Ipamorelin →

Ipamorelin (GHRP) stimulates endogenous GH release, which is redundant when exogenous rhGH is administered. However, ipamorelin may still amplify pulsatility of remaining endogenous secretion in partial GHD or during GH dose titration. Not typically combined in standard clinical practice; more common in experimental or off-label protocols. Limited evidence for additive benefit.

HGH 191AA: Standard dose per indication
Ipamorelin: 100–200 mcg SQ · morning (if used)
Note: Monitor IGF-1 closely; avoid supraphysiological levels
Primary benefit: Theoretical enhancement of pulsatility; limited clinical rationale

+ Tesamorelin

Weak

View Tesamorelin →

Tesamorelin (GHRH analogue) stimulates endogenous GH secretion, which is unnecessary when exogenous rhGH is already provided. Combining both offers no mechanistic advantage and increases cost, side effects, and IGF-1 elevation risk. Not recommended in clinical practice.

Note: Combination not recommended — choose one GH modality
Primary benefit: None — redundant mechanisms

N-Acetyl Epitalon Amidate

+ Thymalin

Moderate

View Thymalin →

Both are Khavinson-school bioregulators with epigenetic mechanisms. Thymalin targets thymic transcription factors for immune function, while Epitalon targets telomerase and pineal-axis genes. Combined use theoretically addresses dual axes of aging: replicative senescence and immune decline. Multi-target bioregulator strategy per Khavinson gerontology framework.

Epitalon: Protocol not defined in indexed literature
Thymalin: Tissue-specific bioregulator · separate dosing
Rationale: Complementary transcriptional targets
Primary benefit: Dual-axis aging intervention: cellular senescence + immune restoration